The stock market’s relentless march upward has pushed the prices of many companies higher. As investors bid up good and bad businesses alike, it can be hard to discern which companies are the best for long-term investors.
That’s especially true in the world of dividend stocks, where income-starved investors face greater temptation by the day to reach for high dividend stocks that....More>>>
The rescue of Europe’s weakest bank just got a lot more expensive.
Monte dei Paschi, the world’s oldest operating bank, will require 8.8 billion ($9.2 billion) to plug a massive hole in its finances. That’s nearly twice the bailout price tag that had been expected.
The Italian lender revealed the larger sum Monday, saying it was based on an estimate from the....More>>>
Finish Line (NASDAQ:FINL) has been a terrific growth story in what has been a pretty beat up sector of retail in the past several quarters but despite this, the stock continues to sport a fairly low valuation. That was true heading into the Q3 earnings report and shares were crushed, making the stock look even more attractively valued. I’ve built my bull case upon....More>>>
In my previous article I stated that ION Geophysical (NYSE:IO) could generate some profits and a positive cash flow during 3Q 2016, and the firm did not disappoint me.
Profit and revenue improvements were mainly driven by the OBS unit that has just concluded a survey in Nigeria, but they are also an important result of the various cost cutting policies that the management has decided to execute....More>>>
Medical device company Endra Life Sciences (NDRA) wants to sell 2 million shares at an expected price of $5.50 per share to raise $11 million in its IPO.
The company is developing enhanced ultrasound technologies that promise to expand the range of treatment options for a variety of indications.
While Endra has a one-year collaboration agreement with GE Healthcare,....More>>>
December 21, 2016: Here are four stocks trading with relatively heavy volume among 56 equities making new 52-week lows in Wednesday’s session. On the NYSE, decliners led advancers by about 120 issues and on the Nasdaq decliners led advancers by about 5 to 3.
Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) dropped about 19% on Wednesday to post a new 52-week low of $4.35 against a 52-week....More>>>